Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.

ABSTRACT:

Background

Paraneoplastic inflammatory syndrome (PIS) with fever and biological inflammation is a rare but severe condition often caused by the systemic production of interleukin 6 (IL-6) by cancer cells. We report on the efficacy of tocilizumab, an anti-IL-6 receptor antibody, in 35 patients with severe PIS.

Patients and methods

All 35 patients with solid cancers (sarcomas, lung carcinoma, and breast carcinoma) diagnosed with a PIS from 2019 to 2024 treated with tocilizumab were analyzed in this single-center study (health authorities' approval R201-004-478). Patients' characteristics and clinical and biological effects of tocilizumab administration are presented.

Results

Thirty-five (97%) patients had paraneoplastic fever. The median performance status (PS) was 2 (r

SUBMITTER: Blay JY 

PROVIDER: S-EPMC11758126 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature